In light of the rapidly changing coronavirus (COVID-19) situation, Troutman Sanders and Pepper Hamilton have postponed the effective date of their previously announced merger until July 1, 2020. The new firm – Troutman Pepper – will feature 1,100+ attorneys across 23 U.S. offices. Read more.
On March 25, the U.S. Department of Justice (DOJ) announced that Duke University agreed to settle a False Claims Act qui tam action alleging widespread misconduct in federally funded research.
A former Duke researcher brought the whistleblower action, alleging that a Duke colleague knowingly submitted falsified research results to the National Institutes of Health (NIH) and the Environmental Protection Agency (EPA) in grant applications and progress reports to obtain tens of millions of dollars in federal grant funding. The whistleblower further alleged that, upon discovering the research fraud, Duke laboratory directors did not disclose the fraud to the government agencies and continued to submit the falsified data to support the university’s research funding. The whistleblower will receive 30 percent of the settlement, or $33.75 million.
These unprecedented allegations of research misconduct rising to a level that violates the False Claims Act, and the sizeable settlement paid by Duke underscore the stakes of alleged noncompliance with the many requirements attached to receiving public research funding. While allegations of research misconduct in federally funded research have increased in recent years, lawsuits and enforcement actions alleging that this misconduct violates the False Claims Act have remained rare. With this high-profile settlement, and huge financial windfall earned by the whistleblower, the looming specter of increased False Claims Act actions should cause research institutions to be more attentive than ever to their research misconduct compliance and reporting obligations.
The Allegations Against Duke University1
Generally speaking, the federal False Claims Act imposes civil and, in some instances, criminal liability on individuals or institutions that knowingly present false or fraudulent claims for payment to the government. Although not traditionally used to pursue alleged research fraud, the submission of false or fraudulent documentation to federal agencies that administer research grants can fall within the scope of the False Claims Act when that documentation includes false or fraudulent research data or otherwise violates applicable rules, policies or certifications.
Here, the whistleblower’s allegations focused on the conduct of Erin Potts-Kant, the clinical research coordinator in Duke University’s Airway Physiology Laboratory, and Dr. William Foster, a research professor in the Division of Pulmonary, Asthma, and Critical Care at Duke and a principal investigator of the Airway Physiology Laboratory. Potts-Kant was responsible for collecting and interpreting clinical data on the effects of pathogens, chemicals and environmental factors on the airways of laboratory mice, with the goal of treating human pulmonary diseases. Foster was the principal investigator who supervised Potts-Kant and bore ultimate responsibility for the laboratory’s research and for applying for and securing grant funding.
During Potts-Kant’s almost eight-year tenure, Foster’s laboratory secured more than $120 million in public grant funding from the NIH and EPA. These extensive research efforts culminated in Potts-Kant and Foster co-authoring more than 38 scientific papers and journals articles, all of which cited federal grant support.
In the qui tam complaint, however, the whistleblower alleged that Potts-Kant’s research results supporting these publications were false and/or fabricated. Specifically, the whistleblower alleged that Potts-Kant deliberately manipulated the cited data or based it on experiments that she intentionally completed incorrectly. In some instances, the whistleblower alleged that there was no raw data at all to support Potts-Kant’s results and that some of the experiments had never been conducted.
The whistleblower also argued that Duke bore False Claims Act liability because it included Potts-Kant’s false and fabricated data in grant applications and progress reports it submitted to the NIH and EPA. The whistleblower alleged that faculty leadership at Duke learned of the extent of Potts-Kant’s research misconduct in March 2013, but did not take appropriate steps to disclose Potts-Kant’s fraud to the government, and also continued to include data obtained by Potts-Kant in grant applications.
Finally, the whistleblower alleged that, before learning about Potts-Kant’s misconduct in March 2013, principal investigators in the Pulmonary Division received warnings of research misconduct by Potts-Kant in Foster’s laboratory but did not take appropriate steps to investigate and address those warnings, as required by federal law and Duke’s internal policies, and in accordance with Duke’s obligations as a grant recipient.
Key Takeaways for Research Institutions
Duke’s settlement of this whistleblower action with DOJ highlights the need for strict compliance and vigilant oversight of research activities by any institution that applies for and/or receives public grant money. Given the outcome here, it would not be surprising to see a spate of similar allegations and qui tam suits in the coming months and years. Federally funded research institutions would be wise to take the following steps to protect themselves from similar allegations and False Claims Act exposure.
It is incumbent on research institutions to appreciate and address the significant risks that are implicated by malfeasance committed by their employees in federally funded research. The Duke settlement presents, perhaps, an extreme example of how things can go wrong when fraud occurs, but the settlement illustrates that a research institution’s liability under the False Claims Act is very real when there is falsification of federally funded research.
Given the severe penalties imposed by the False Claims Act, and the ability for whistleblowers to reap significant financial benefits by pursuing qui tam cases on behalf of the government, research institutions should learn from the Duke case and make every effort to protect themselves from future liability by taking appropriate preventive action and consulting with legal counsel the moment research fraud issues arise.
1 All details of the alleged conduct stem from the unproven allegations in the underlying qui tam complaint. See Am. Compl., United States ex rel. Thomas v. Duke Univ., No. 1:17-cv-00276 (M.D.N.C. Nov. 13, 2015).
The material in this publication was created as of the date set forth above and is based on laws, court decisions, administrative rulings and congressional materials that existed at that time, and should not be construed as legal advice or legal opinions on specific facts. The information in this publication is not intended to create, and the transmission and receipt of it does not constitute, a lawyer-client relationship.